Clinical trials: Fat; Liver
Colorectal Cancer, Liver Metastasis Colon Cancer
The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
The CLiFF Study will assess changes in liver function and liver fat in patients with colorectal liver metastases (CLM) undergoing pre-operative chemotherapy before liver resection.
- Conditions
- Colorectal Cancer, Liver Metastasis Colon Cancer, Chemotherapy Effect, Obesity
- Trial name
- CLiFF (NCT03562234)
- Testing
- MR, LiMAx
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Manchester
Obstructive Sleep Apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease
Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
- Trial name
- OSA/MAFLD (NCT07716995)
- Volunteers
- 127 people
- Sponsor
- Assiut University
Metabolism and Nutrition Disorder, Liver Diseases
The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease
In this study, 18-60 years old patients with metabolic associated fatty liver disease（MAFLD） will be recruited to test the intervention effect of vegetarian diet.
- Conditions
- Metabolism and Nutrition Disorder, Liver Diseases, Obesity, Diet, Healthy
- Trial name
- NCT05443581
- Testing
- dietary intervention
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Hepatic Steatosis
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults.
- Trial name
- BIPEH (NCT06394206)
- Testing
- Specialized Unit, Usual Follow-Up
- Where
- Spain
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
NAFLD, NASH - Nonalcoholic Steatohepatitis
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
Magnetic resonance imaging (MRI) is used to measure liver fat content and fatty tissues in the body, and magnetic resonance elastography (MRE) is used to measure liver stiffness.
- Trial name
- NCT04591106
- Testing
- Magnetic resonance imaging (MRI), Magnetic resonance elastography (MRE), Prototype MRE soft flexible passive transducer paddle
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Non-Alcoholic Fatty Liver Disease
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease.
- Trial name
- MODIFY (NCT05209100)
- Testing
- Sigmoidoscopy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Total Parenteral Nutrition-induced Cholestasis
Compassionate Use of Omegaven IV Fat Emulsion
The purpose of the study is to provide use of Omegaven in children with life threatening Total Parenteral Nutrition (TPN) associated cholestasis when all other medical and surgical treatments/therapies have been either…
- Trial name
- NCT01323907
- Testing
- Omegaven IV lipid emulsion
- Where
- United States
- Sponsor
- Sivan Kinberg
Non-Alcoholic Steatohepatitis
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
The term non-alcoholic fatty liver disease (NAFLD) is used to describe a range of chronic liver diseases that range from steatosis to steatohepatitis, advanced fibrosis, cirrhosis, or excessive alcohol consumption or other causes…
- Trial name
- NCT05065593
- Testing
- resistance and aerobic exercise, physical activity recommendation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
NAFLD
Copeptin and Nonalcoholic Fatty Liver Disease
Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver disease (NAFLD), and therefore…
- Trial name
- NCT03254563
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Obesity, Diabetes Mellitus, Type 2
Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD
This study is designed as a prospective pilot study for longitudinal assessment of fecal microbiome related to medical and surgical weight loss.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, NAFLD
- Trial name
- NCT04263376
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
NAFLD
Lifestyle Modification in the Treatment of NAFLD.
The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD/NASH in patients with metabolic syndrome.
- Trial name
- NCT05816915
- Testing
- Cognitive behavioral therapy
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- General University Hospital, Prague
Obesity, NAFLD
ER Stress in NAFLD
The investigators overall hypothesis is that exacerbation of endoplasmic reticulum (ER) stress in the liver is associated with significant alterations in phosphatidylcholines that drive the NASH phenotype in obese humans.
- Trial name
- NCT01807910
- Testing
- methyl-D9-choline
- Where
- United States
- Sponsor
- Vanderbilt University
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Healthy
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.
- Trial name
- NCT03597217
- Testing
- PF-05221304
- Where
- Japan
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis, Type 2 Diabetes Mellitus
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT02769091)
- Testing
- TEV-45478
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Liver Steatoses
Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients
The aim of this study was to examine the association between metabolic associated fatty liver disease (MAFLD) in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy.
- Trial name
- NCT06443723
- Testing
- USG, blood tests, waist, hip, height and blood pressure measurements
- Where
- Turkey (Türkiye)
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
NAFLD Cirrhosis
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function…
- Trial name
- NCT05849220
- Testing
- Dapagliflozin, Standard of Care
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non Alcoholic Fatty Liver
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non Invasive Methods.And correlation between lab and radiological methods .
- Trial name
- NCT04553796
- Testing
- fibroscan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.